The role of 18F-FDG PET/MRI in assessing pathological complete response to neoadjuvant chemotherapy in patients with breast cancer: a systematic review and meta-analysis
Contact us if these videos are not relevant.
Contact us if these videos are not relevant.
View abstract on PubMed
Summary
This summary is machine-generated.Positron emission tomography-computed tomography (PET/MRI) with 18F-FDG is more effective than MRI alone for predicting neoadjuvant chemotherapy response in breast cancer patients. This advanced imaging technique offers improved sensitivity and specificity for treatment assessment.
Area Of Science
- Oncology
- Radiology
- Medical Imaging
Background
- Breast cancer (BC) treatment response assessment is crucial for personalized therapy.
- Neoadjuvant chemotherapy (NAC) is a standard treatment for many BC patients.
- Accurate prediction of pathological response to NAC is essential for optimizing treatment strategies.
Purpose Of The Study
- To evaluate the diagnostic performance of 18F-2-[18F]-fluoro-2-deoxy-d-glucose (FDG) PET/MRI in predicting pathological response to NAC in breast cancer patients.
- To compare the efficacy of 18F-FDG PET/MRI with MRI alone in assessing treatment response.
- To provide evidence for the clinical utility of advanced imaging in breast cancer management.
Main Methods
- Systematic literature search across major databases (PubMed, Scopus, Embase, Science Direct).
- Meta-analysis of six studies involving 239 breast cancer patients.
- Statistical analysis using random-effect models (STATA v14), assessing heterogeneity with chi-squared and I2 index, and publication bias with funnel plots and Egger tests.
Main Results
- 18F-FDG PET/MRI demonstrated a pooled sensitivity of 0.91 and specificity of 0.62 for predicting response to NAC.
- MRI alone showed a pooled sensitivity of 0.78 and specificity of 0.56.
- The analysis included data from 239 patients across six studies, with high heterogeneity observed.
Conclusions
- 18F-FDG PET/MRI is a more sensitive and specific imaging modality than MRI alone for predicting pathological response to neoadjuvant chemotherapy in breast cancer patients.
- This finding supports the integration of 18F-FDG PET/MRI into clinical practice for treatment response assessment in breast cancer.
- Further research may explore cost-effectiveness and broader clinical application of this combined imaging technique.
Contact us if these videos are not relevant.
Contact us if these videos are not relevant.
Related Concept Videos
Positron emission tomography (PET) is a medical imaging technique involving radiopharmaceuticals — substances that emit short-lived radiation. Although the first PET scanner was introduced in 1961, it took 15 more years before radiopharmaceuticals were combined with the technique and revolutionized its potential.
One of the main requirements of a PET scan is a positron-emitting radioisotope, which is produced in a cyclotron and then attached to a substance used by the part of the body...
Positron Emission Tomography (PET) is a medical imaging technique that provides crucial insights into the body's physiological functions at a molecular level. It is an indispensable resource for diagnosing, staging, and monitoring various illnesses, notably cancer, neurological disorders, and cardiovascular conditions.
Fundamental Principles of PET
Radioactive Tracer: PET involves using biologically active molecules labeled with radioactive isotopes, known as tracers or radiotracers. The...
Radiological investigations are paramount in the diagnosis and management of various pulmonary diseases. Two essential investigations are the Pulmonary Angiogram and the Positron Emission Tomography (PET) Scan.
Pulmonary Angiogram
A Pulmonary Angiogram is an invasive procedure involving injecting a contrast medium through a catheter threaded into the pulmonary artery or the right side of the heart to visualize the pulmonary vasculature. Computed Tomography (CT) scans have mainly replaced this...